Tracking the pathogen of coronavirus disease 2019 (COVID-19) in live subjects may help
estimate the spatiotemporal distribution of SARS-CoV-2 infection
in
vivo
. This study developed a positron emission tomography (PET) tracer of the
S2 subunit of spike (S) protein for imaging SARS-CoV-2. A pan-coronavirus inhibitor, EK1
peptide, was synthesized and radiolabeled with copper-64 after being conjugated with
1,4,7-triazacyclononane-1,4,7-triyl-triacetic acid (NOTA). The
in vitro
stability tests indicated that [
64
Cu]Cu-NOTA-EK1 was stable up to 24 h both
in saline and in human serum. The binding assay showed that [
64
Cu]Cu-NOTA-EK1
has a nanomolar affinity (
K
i
= 3.94 ± 0.51 nM) with the
S-protein of SARS-CoV-2. The cell uptake evaluation used HEK293T/S
+
and
HEK293T/S
–
cell lines that showed that the tracer has a high
affinity with the S-protein on the cellular level. For the
in vivo
study, we tested [
64
Cu]Cu-NOTA-EK1 in HEK293T/S
+
cell
xenograft-bearing mice (
n
= 3) and pseudovirus of SARS-CoV-2-infected
HEK293T/ACE2 cell bearing mice (
n
= 3). The best radioactive
xenograft-to-muscle ratio (
X
/
N
xenograft
8.04 ± 0.99,
X
/
N
pseudovirus
6.47
± 0.71) was most evident 4 h postinjection. Finally, PET imaging in the surrogate
mouse model of beta-coronavirus, mouse hepatic virus-A59 infection in C57BL/6 J mice
showed significantly enhanced accumulation in the liver than in the uninfected mice
(1.626 ± 0.136 vs 0.871 ± 0.086 %ID/g,
n
= 3,
P
< 0.05) at 4 h postinjection. In conclusion, our experimental
results demonstrate that [
64
Cu]Cu-NOTA-EK1 is a potential molecular imaging
probe for tracking SARS-CoV-2 in extrapulmonary infections in living subjects.